[Pubmed] Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three
Posté : 11 juin 2025 12:00
Front Immunol. 2025 May 27;16:1552521. doi: 10.3389/fimmu.2025.1552521. eCollection 2025.
ABSTRACT
Myasthenia gravis (MG) and connective tissue diseases (CTD) are both B-cell-mediated, antibody-associated autoimmune diseases that share similar mechanisms of immune dysfunction. The coexistence of MG and CTD is a rare phenomenon, and its management remains challenging. Here, we report three cases of coexisting MG and CTD-specifically systemic lupus erythematosus and Sjögren's syndrome, and all three patients presented significant improvement 4 weeks after initiation of treatment with telitacicept. Minimal symptom expression (MSE) was achieved after 4, 6, and 7 weeks of treatment with telitacicept, for patients one-to-three, respectively. This therapy also enabled a reduction in prednisone dosage, with clinical symptoms of CTD remaining well controlled. These findings present preliminary evidence supporting Telitacicept as an effective treatment and a double-target therapy for the management of MG-CTD.
PMID:40496856 | PMC:PMC12149098 | DOI:10.3389/fimmu.2025.1552521
Source: https://pubmed.ncbi.nlm.nih.gov/4049685 ... t9+e462414